According to new research, a biomarker signature can predict how well kidney cancer patients will respond to immunotherapy before treatment even starts
Biomarkers Found for Response to Kidney Cancer Immunotherapy miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
The number of immune cells in and around kidney tumors, the amount of dead cancer tissue, and mutations to a tumor suppressor gene called PBRM1 form a biomarker signature that can predict before treatment begins how well patients with kidney cancer will respond to immunotherapy, according to new research directed by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.
Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced the appointment of Janis M. Taube, M.D., M.Sc., a leading pathologist and
E-Mail
IMAGE: The AstroPath platform allows for the assessment of the level of expression of a given marker on individual cells, while maintaining information on their spatial location. Shown here is. view more
Credit: Seyoun Park, Ph.D.
Pairing sky-mapping algorithms with advanced immunofluorescence imaging of cancer biopsies, researchers at The Mark Foundation Center for Advanced Genomics and Imaging at Johns Hopkins University and the Bloomberg~Kimmel Institute for Cancer Immunotherapy developed a robust platform to guide immunotherapy by predicting which cancers will respond to specific therapies targeting the immune system.
A new platform, called AstroPath, melds astronomic image analysis and mapping with pathology specimens to analyze microscopic images of tumors.